The human microbiome is no longer viewed as a silent passenger but as a dynamic, metabolic organ that dictates the boundary between health and disease. Among the diverse phyla that inhabit our gut, the genus Prevotella has emerged as a focal point of intense scientific inquiry. Specifically, Prevotella stercorea represents a frontier in Live Biotherapeutic Product (LBP) development. As a premier Contract Research Organization (CRO) dedicated to preclinical excellence, Creative Biolabs recognizes that unlocking the potential of this specific strain requires more than just standard assays; it requires a deep, mechanistic understanding of anaerobic microbiology and host-microbe interactions. We invite you to explore how our specialized research and production services can transform P. stercorea from a genomic sequence into a validated therapeutic candidate.
Overview: The Rising Profile of Prevotella stercorea
Prevotella stercorea is a Gram-negative, obligate anaerobic bacterium first isolated from human feces. It is a cornerstone species of the "non-Western" gut enterotype, typically found in high abundance in individuals who consume diets rich in plant-based fibers. Unlike its relative P. copri, P. stercorea possesses unique metabolic signatures and genomic features that distinguish its functional role within the gut ecosystem. It is highly adept at degrading complex polysaccharides, producing short-chain fatty acids (SCFAs) like acetate and succinate, which are essential for maintaining intestinal epithelial integrity and modulating systemic inflammation.
Developing P. stercorea as an LBP involves navigating its extreme sensitivity to oxygen and its specific growth requirements. Our mission is to provide the high-fidelity data and material necessary to move these programs through the developmental pipeline with confidence.
Preclinical Research Services for Prevotella stercorea
As a specialized CRO, Creative Biolabs provides a full spectrum of research services to support the development of P. stercorea as a Live Biotherapeutic Product (LBP). Our integrated platform covers:
To bridge the gap between discovery and preclinical trials, we provide a flexible, non-GMP lab-scale production platform tailored for fastidious anaerobes.
-
Isolation & Identification: High-throughput isolation under strict anaerobic conditions followed by polyphasic taxonomy and molecular identification.
-
Genomic Profiling: Whole Genome Sequencing (WGS) to identify antibiotic resistance genes (ARGs) and virulence factors.
-
Metabolic Mapping: Profiling SCFAs and other metabolites using LC-MS/MS and Gas Chromatography.
In Vitro andIn Vivo Efficacy Assessment
-
Gut Barrier Function Testing: Using Caco-2 models to measure TEER and mucin production.
-
Immune System Modulation: Screening for cytokine profiles (IL-10, TNF-α) in response to the strain.
-
Disease-Specific Animal Models: Utilizing germ-free and humanized microbiota mouse models for oncology, metabolic, and inflammatory disease research.
Products for Prevotella stercorea Research
To support your internal R&D, we provide high-quality standardized products:
|
Product Name
|
Catalog No.
|
Target
|
Product Overview
|
Size
|
Datasheet
|
Price
|
|
Prevotella histicola
|
LBST-009FG
|
Prevotella
|
Prevotella histicola is Gram-negative bacillus that are obligately anaerobic, vary in pigmentation and are non-motile.
|
200 µg
|
Datasheet
|
$1988.00
|
|
Prevotella histicola Genomic DNA
|
LBGF-0925-GF331
|
Prevotella DNA
|
This product contains high-quality, intact genomic DNA isolated from Prevotella histicola Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
|
5 µg
|
Datasheet
|
$1120.00
|
Research Application: Prevotella stercorea in Disease Treatment
The therapeutic landscape for Prevotella stercorea is expanding rapidly. Current research is moving toward mechanistic validation in several key areas:
1. Oncology and Immunotherapy Enhancement
Specific strains are being researched for their ability to enhance the efficacy of Immune Checkpoint Inhibitors (ICIs). By increasing T-cell proliferation and augmenting Interferon-gamma (IFN-γ) secretion, P. stercorea may help turn "cold" tumors "hot."
Its ability to ferment dietary fiber into succinate can act as a substrate for intestinal gluconeogenesis, which is linked to improved glucose tolerance and insulin sensitivity, offering potential for Type 2 Diabetes and obesity treatments.
Longitudinal studies suggest that a high abundance of P. stercorea is associated with protection against common enteric infections, likely through competitive exclusion and fortification of the gut barrier.
Research focuses on identifying specific lineages that induce Regulatory T-cells (Tregs) to treat inflammatory bowel disease (IBD) and systemic autoimmunity.
Our Advantages
Total Anaerobic Expertise
Our facilities include anaerobic chambers with internal HEPA filtration for aseptic, anaerobic filling, ensuring that even the most oxygen-sensitive strains remain viable.
Low Cost & Low Risk
Our lab-scale production services are designed for research use, requiring less capital and time than large-scale manufacturing while allowing for quick adjustments in strategy.
Customizable Production
We prioritize client needs, adjusting fermentation and stabilization strategies based on specific project goals.
Regulatory Alignment
All preclinical protocols are designed with future IND requirements in mind, focusing on identity, purity, and potency.
The transition of Prevotella stercorea from a gut commensal to a therapeutic powerhouse is paved with scientific challenges that demand precision and specialized technology. As we have outlined, its potential spans from metabolic health to oncology, but the key to unlocking this potential lies in the preclinical phase. Identifying the right strain, proving its mechanism of action, and ensuring its stability through specialized production are the pillars of success.
At our CRO, we are more than just a service provider; we are your intellectual partners in the microbiome revolution. Our facility is purpose-built to handle the complexities of anaerobic life, and our team is driven by the goal of bringing transformative Live Biotherapeutics to patients in need. By combining state-of-the-art lab-scale production with sophisticated efficacy models, we provide the clarity and confidence you need to move forward.
Let us help you unlock the power of Prevotella stercorea. Contact our scientific team today to discuss your project requirements.
Frequently Asked Questions (FAQs)
How do you ensure the CFU count in your freeze-dried powder?
We perform preliminary experiments to understand the strain's specific growth kinetics. After formal fermentation and freeze-drying, we conduct rigorous counting and viability testing to ensure compliance with your specifications.
Can you produce extracellular vesicles for this specific strain?
Yes. We have specialized equipment, including homogenizer mixers and purification tools, to isolate and characterize BEVs from P. stercorea cultures.
What is the benefit of lab-scale over large-scale production at this stage?
Lab-scale production is more flexible and cost-effective for early development. It allows for small-batch testing and iterative adjustments that are not feasible in a large-scale GMP environment.
